Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles.
暂无分享,去创建一个
Yusuke Nakamura | Tatsuhiko Tsunoda | Hidewaki Nakagawa | Yoichi Mizutani | Kenji Tamura | Hiromi Kumon | Mikio Namiki | Hideyuki Akaza | Tsuneharu Miki | Kenjiro Kohri | Hiroki Yoshioka | Ryo Takata | Wataru Obara | Yusuke Nakamura | T. Tsunoda | Y. Mizutani | T. Miki | K. Tamura | H. Akaza | K. Tozawa | H. Nakagawa | R. Takata | T. Shuin | T. Fujioka | M. Furihata | W. Obara | K. Kohri | Y. Daigo | H. Kumon | Y. Nasu | S. Ashida | M. Namiki | Yataro Daigo | Tomoaki Fujioka | T. Shimazui | Hiroki Yoshioka | H. Konaka | N. Tanji | M. Yokoyama | Mutsuo Furihata | Taro Shuin | Yasutomo Nasu | Keiichi Tozawa | Hiroyuki Konaka | Shingo Ashida | Nozomu Tanji | Masayoshi Yokoyama | Toru Shimazui
[1] P. Kantoff,et al. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] A W Partin,et al. Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. , 2001, The Journal of urology.
[3] D. Tindall,et al. Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. , 2002, Cancer research.
[4] D. Tindall,et al. Androgen receptor signaling in androgen-refractory prostate cancer. , 2001, Journal of the National Cancer Institute.
[5] C. Tangen,et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. , 2004, The New England journal of medicine.
[6] Yusuke Nakamura,et al. ANLN plays a critical role in human lung carcinogenesis through the activation of RHOA and by involvement in the phosphoinositide 3-kinase/AKT pathway. , 2005, Cancer research.
[7] J. Fraumeni,et al. Geographic patterns of prostate cancer in the United States. , 1978, Journal of the National Cancer Institute.
[8] Desok Kim,et al. Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes. , 1998, Cancer research.
[9] T. Golub,et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. , 2006, Cancer research.
[10] Desok Kim,et al. The Androgen Axis in Recurrent Prostate Cancer , 2004, Clinical Cancer Research.
[11] K. Grigor,et al. Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer , 2003, British Journal of Cancer.
[12] G. Schwartz,et al. Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation , 1992, Cancer.
[13] D. Feldman,et al. The development of androgen-independent prostate cancer , 2001, Nature Reviews Cancer.
[14] M. Webber,et al. Cholecalciferol (Vitamin D3) Inhibits Growth and Invasion by Up-regulating Nuclear Receptors and 25-Hydroxylase (CYP27A1) in Human Prostate Cancer Cells , 2005, Clinical & Experimental Metastasis.
[15] K. Lee,et al. LH induces orphan nuclear receptor Nur77 gene expression in testicular Leydig cells. , 2001, Endocrinology.
[16] J. Mesirov,et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. , 1999, Science.
[17] Yusuke Nakamura,et al. PCOTH, a novel gene overexpressed in prostate cancers, promotes prostate cancer cell growth through phosphorylation of oncoprotein TAF-Ibeta/SET. , 2005, Cancer research.
[18] R L Vessella,et al. Advances in Brief Amplification and Overexpression of Androgen Receptor Gene in Hormone-Refractory Prostate Cancer 1 , 2001 .
[19] S. Devesa,et al. Trends and patterns of prostate cancer: what do they suggest? , 2001, Epidemiologic reviews.
[20] Henrik Grönberg,et al. Prostate cancer epidemiology , 2003, The Lancet.
[21] D. Tindall,et al. Mechanisms of androgen-refractory prostate cancer. , 2004, The New England journal of medicine.
[22] H. Klocker,et al. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. , 1998, Cancer research.
[23] L. Chung. Prostate carcinoma bone‐stroma interaction and its biologic and therapeutic implications , 2003, Cancer.
[24] R. Vessella,et al. Molecular determinants of resistance to antiandrogen therapy , 2004, Nature Medicine.
[25] H. Klocker,et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. , 1994, Cancer research.
[26] Noah Craft,et al. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase , 1999, Nature Medicine.
[27] I. Tannock,et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.
[28] D. Ghosh,et al. Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases , 2004, Cancer Research.
[29] E. Latulippe,et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. , 2004, The American journal of pathology.
[30] S. Rafii,et al. Cancer interaction with the bone microenvironment: a workshop of the National Institutes of Health Tumor Microenvironment Study Section. , 2006, The American journal of pathology.
[31] W. Isaacs,et al. Focus on prostate cancer. , 2002, Cancer cell.
[32] Matthias Frisch,et al. Androgen receptor binding sites identified by a GREF_GATA model. , 2005, Journal of molecular biology.
[33] Yusuke Nakamura,et al. Molecular Features of the Transition from Prostatic Intraepithelial Neoplasia (PIN) to Prostate Cancer , 2004, Cancer Research.
[34] B. Calnan,et al. Requirement for the orphan steroid receptor Nur77 in apoptosis of T-cell hybridomas , 1994, Nature.
[35] S. Balk,et al. Androgen receptor as a target in androgen-independent prostate cancer. , 2002, Urology.
[36] H. Scher,et al. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.